EE518 An Updated Cost-Effectiveness Analysis of Axicabtagene Ciloleucel in Second-Line Large B-Cell Lymphoma Patients in the United States
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.783
https://www.valueinhealthjournal.com/article/S1098-3015(23)03913-X/fulltext
Title :
EE518 An Updated Cost-Effectiveness Analysis of Axicabtagene Ciloleucel in Second-Line Large B-Cell Lymphoma Patients in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03913-X&doi=10.1016/j.jval.2023.09.783
First page :
Section Title :
Open access? :
No
Section Order :
10270